Shorter Radiation Courses Become Standard Care for Localized Prostate Cancer in New Guideline

Men with localized prostate cancer who choose radiation therapy now have clearer guidance on finishing treatment in far fewer sessions. The American Society for Radiation Oncology has issued an updated clinical guideline recommending shorter courses of external beam radiation therapy across all risk groups of localized disease, and formally elevating five-session stereotactic body radiation therapy, known as SBRT, to a standard option for many patients. The guideline, published in Practical Radiation Oncology, replaces the society’s 2018 recommendations and reflects what its authors describe as a substantially matured evidence base showing that compressed treatment schedules can maintain cancer control while reducing the overall burden of care.

The scale of the disease gives the update broad relevance. Prostate cancer is the second most common cancer among men in the United States after skin cancer, and roughly one in eight men will be diagnosed during their lifetime. In 2026, nearly 334,000 new cases are expected among U.S. adults. When the disease is caught while still confined to the prostate, outcomes are generally excellent, and patients typically weigh several effective approaches according to their individual priorities. For those who select radiation, external beam radiation therapy remains a standard definitive treatment, and the central question addressed by the new document is not whether to irradiate the prostate but how to schedule the dose.

Hypofractionation is the technical term at the heart of the guideline. Conventional radiation therapy for prostate cancer spreads a total dose over many small daily treatments. Hypofractionated delivery instead uses a higher dose per session while keeping the overall therapeutic effect similar, which shortens the course. Moderate hypofractionation typically runs four to six weeks. Ultrahypofractionation compresses treatment much further, most commonly as SBRT, allowing patients to finish in five sessions over one to two weeks.

The headline recommendation is straightforward: for patients with localized prostate cancer receiving external beam therapy to the prostate, with or without treatment of the seminal vesicles, moderate hypofractionation is recommended over conventional fractionation across all risk groups. The task force grounds this in randomized trials involving more than 7,000 patients, with long-term data showing comparable cancer control, side effect profiles and quality of life. Notably, the recommendation applies regardless of patient age, comorbidity, anatomy or baseline urinary function, and the guideline states that decisions about androgen deprivation therapy should be made independently of the choice of fractionation regimen.

The second major shift concerns ultrahypofractionation. The guideline strongly recommends it as a standard option for many patients, including those with intermediate-risk disease receiving therapy to the prostate and seminal vesicles, and for low-risk patients who decline active surveillance and choose radiation instead. For men with high-risk or very high-risk disease, ultrahypofractionated therapy is conditionally recommended as an option. “SBRT has moved from a promising alternative to a standard treatment option for many patients with localized prostate cancer,” said guideline task force chair Scott C. Morgan, a radiation oncologist at The Ottawa Hospital and professor of radiation oncology at the University of Ottawa. He added that the recommendations give clinicians clear direction on using shorter-course treatment safely while preserving the outcomes patients expect from definitive radiation therapy.

Not every patient is an ideal candidate for the most compressed schedules. For patients with significant baseline urinary symptoms, the guideline conditionally recommends moderate hypofractionation over ultrahypofractionation, noting that the five-session approach may increase the risk of treatment-related urinary side effects in men with substantial pre-existing lower urinary tract symptoms. This caveat illustrates the guideline’s broader emphasis on shared decision-making, which runs through the document particularly where options vary by risk group, urinary function and patient preference. Elective pelvic nodal treatment adds another layer of nuance: moderate hypofractionation to the prostate with concurrent conventional or near-conventional radiation to the pelvic lymph nodes is recommended using a single-phase plan, while ultrahypofractionated delivery to pelvic nodes is conditionally recommended only within a clinical trial.

The guideline is unusually specific about doses and targets. For moderately hypofractionated therapy, recommended schedules include 6000 to 6200 cGy delivered in 20 fractions or 7000 cGy in 28 fractions. For ultrahypofractionated therapy, a dose of 3625 to 4000 cGy in five fractions is conditionally recommended, and regimens using fewer than five fractions are not endorsed outside of a clinical trial. Target volumes vary by risk: low-risk patients declining surveillance may be treated to the prostate alone, while higher-risk disease calls for inclusion of at least part of the seminal vesicles, with focal intraprostatic boost potentially considered for selected patients whose dominant lesion is visible on MRI.

The guideline devotes considerable attention to precision and safety in treatment planning and delivery. Best practices emphasize MRI-informed planning when appropriate, daily motion management and intensity modulated radiation therapy. The guideline also conditionally recommends intrafraction tracking for patients receiving ultrahypofractionated treatment and discusses rectal spacers as part of shared decision-making. “The evidence supporting hypofractionation is now much stronger in the years since ASTRO’s previous guideline was published,” said task force vice chair Karen Hoffman, a professor of radiation oncology and the Mays Radiation Oncology Center Medical Director at The University of Texas MD Anderson Cancer Center. She noted that the guideline also reflects how treatment planning has evolved, including greater use of daily image guidance and more precise approaches to managing motion during treatment.

Behind the clinical recommendations lies an equity argument. In national datasets, use of hypofractionated radiation therapy has varied by age, race, socioeconomic factors and treatment setting. Because shorter courses can reduce travel, time away from work and other burdens associated with care, the guideline states that equitable access to high-quality hypofractionated treatment should remain a priority.

The guideline itself was built through a formal process rather than expert opinion alone. A multidisciplinary task force of radiation, medical and urological oncologists, along with a medical physicist and a patient representative, developed the document in collaboration with the American Society of Clinical Oncology, the American Urological Association, the European Society for Radiotherapy and Oncology and the Society of Urologic Oncology, and it has been endorsed by the AUA, ESTRO and SUO. Its recommendations rest on a systematic evidence review funded by the Patient-Centered Outcomes Research Institute and conducted by the Agency for Healthcare Research and Quality, supplemented by ASTRO’s guideline development process and expert consensus where evidence was limited. The society frames its guidelines as tools to promote individualized, shared decision-making, not as rules that supersede the informed judgment of individual physicians and patients — a fitting close for a document whose central message is that fewer trips to the treatment machine can now be offered with confidence, provided the right patient receives the right schedule with the right technical safeguards.

Subject of Research: Shortened-course radiation therapy schedules for localized prostate cancer in an updated ASTRO clinical practice guideline

Article Title: ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Article References: ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, radiation therapy, hypofractionation, SBRT, ASTRO, clinical guideline, external beam radiation therapy, urological oncology, cancer treatment, shared decision-making, Practical Radiation Oncology, treatment burden